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Abstract The degree and rate of clot contraction (retraction)
in systemic lupus erythematosus (SLE) patients, especially in
those with a high level of anti-double stranded DNA (dsDNA)
antibodies in the blood, was significantly reduced compared to
healthy donors. We hypothesized that this effect was caused
by the anti-dsDNA antibodies. To test this assumption, we
investigated the kinetics of blood clot contraction in vitro in
the absence and presence of anti-dsDNA antibodies purified
from the blood serum of SLE patients. The degree of clot
contraction was increased immediately after addition of the
anti-DNA antibodies in a concentration-dependent manner.
This stimulating effect was abrogated by a monoclonal anti-
body against the platelet Fc-receptor. On the contrary, after
prolonged incubation (for hours) of the blood samples with
the anti-DNA antibodies, the extent of clot contraction was
significantly reduced. These results suggest that anti-
dsDNA antibodies in SLE induce Fc-receptor-mediated
chronic platelet hyperactivation, resulting in platelet ex-
haustion and dysfunction, including reduced contractility.
The impaired contraction of blood clots and thrombi
caused by autoantibodies may be an important pathogenic
mechanism that affects the course and outcomes of throm-
botic complications in SLE.
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1 Introduction
Systemic lupus erythematosus (SLE) is a chronic autoimmune
disease that affects multiple organs and tissues, resulting in
diverse symptoms and outcomes. It is characterized by pro-
duction of antibodies (Abs) against a variety of autoantigens,
specifically against double stranded DNA (dsDNA) [1].
Platelets are a well-known target for anti-phospholipid Abs
[2] that alter platelet function in SLE [3] and predispose to
thrombosis [4]. It is unclear whether anti-dsDNAAbs can also
contribute to thrombotic complications in SLE. Blood clots
and thrombi are known to undergo volume shrinkage driven
by contracting platelets, the process named clot contraction or
retraction [5, 6]. Despite its potential clinical importance in
modulating vessel obstruction and blood flow, the mechanical
remodel ing of blood clot and thrombi has been
underestimated and understudied [7]. Here we studied the
effect of anti-dsDNA Abs isolated form the blood of SLE
patients on the ability of platelets to squeeze blood clots.
2 Materials and Methods
Blood from SLE patients and healthy donors was withdrawn
using a protocol approved by the Ethical Committee of Kazan
State Medical University. Only patients who were not treated
with anti-coagulants or anti-platelet drugs were included in the
study. Blood samples of 37 SLE patients were analyzed, of
which the activity of anti-dsDNA Abs was less than 100 ME/
ml in 23 (63%) and > 100ME/ml in 14 (37%). Blood samples
from 60 healthy donors were used as a control. The SLE
patients and control subjects were comparable by the age
(37 ± 2 vs. 34 ± 2 years, respectively) and sex (women com-
prised 79 vs. 69%, respectively).
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